Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. / Shadid, Samyah; Abosi-Appeadu, Kessewa; De Maertelaere, Anne-Sophie; Defreyne, Justine; Veldeman, Laurens; Holst, Jens J.; Lapauw, Bruno; Vilsboll, Tina; T'Sjoen, Guy.
I: Diabetes Care, Bind 43, Nr. 2, 2020, s. 411-417.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People
AU - Shadid, Samyah
AU - Abosi-Appeadu, Kessewa
AU - De Maertelaere, Anne-Sophie
AU - Defreyne, Justine
AU - Veldeman, Laurens
AU - Holst, Jens J.
AU - Lapauw, Bruno
AU - Vilsboll, Tina
AU - T'Sjoen, Guy
PY - 2020
Y1 - 2020
N2 - OBJECTIVE The long-term influences of sex hormone administration on insulin sensitivity and incretin hormones are controversial. We investigated these effects in 35 transgender men (TM) and 55 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) study. RESEARCH DESIGN AND METHODS Before and after 1 year of gender-affirming hormone therapy, body composition and oral glucose tolerance tests (OGTTs) were evaluated. RESULTS In TM, body weight (2.8 +/- 1.0 kg; P < 0.01), fat-free mass (FFM) (3.1 +/- 0.9 kg; P < 0.01), and waist-to-hip ratio (-0.03 +/- 0.01; P < 0.01) increased. Fasting insulin (-1.4 +/- 0.8 mU/L; P = 0.08) and HOMA of insulin resistance (HOMA-IR) (2.2 +/- 0.3 vs. 1.8 +/- 0.2; P = 0.06) tended to decrease, whereas fasting glucose (-1.6 +/- 1.6 mg/dL), glucose-dependent insulinotropic polypeptide (GIP) (-1.8 +/- 1.0 pmol/L), and glucagon-like peptide 1 (GLP-1) (-0.2 +/- 1.1 pmol/L) were statistically unchanged. Post-OGTT areas under the curve (AUCs) for GIP (2,068 +/- 1,134 vs. 2,645 +/- 1,248 [pmol/L] x min; P < 0.01) and GLP-1 (2,352 +/- 796 vs. 2,712 +/- 1,015 [pmol/L] x min; P < 0.01) increased. In TW, body weight tended to increase (1.4 +/- 0.8 kg; P = 0.07) with decreasing FFM (-2.3 +/- 0.4 kg; P < 0.01) and waist-to-hip ratio (-0.03 +/- 0.01; P < 0.01). Insulin (3.4 +/- 0.8 mU/L; P < 0.01) and HOMA-IR (1.7 +/- 0.1 vs. 2.4 +/- 0.2; P < 0.01) rose, fasting GIP (-1.4 +/- 0.8 pmol/L; P < 0.01) and AUC GIP dropped (2,524 +/- 178 vs. 1,911 +/- 162 [pmol/L] x min; P < 0.01), but fasting glucose (-0.3 +/- 1.4 mg/dL), GLP-1 (1.3 +/- 0.8 pmol/L), and AUC GLP-1 (2,956 +/- 180 vs. 2,864 +/- 93 [pmol/L] x min) remained unchanged. CONCLUSIONS In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization.
AB - OBJECTIVE The long-term influences of sex hormone administration on insulin sensitivity and incretin hormones are controversial. We investigated these effects in 35 transgender men (TM) and 55 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) study. RESEARCH DESIGN AND METHODS Before and after 1 year of gender-affirming hormone therapy, body composition and oral glucose tolerance tests (OGTTs) were evaluated. RESULTS In TM, body weight (2.8 +/- 1.0 kg; P < 0.01), fat-free mass (FFM) (3.1 +/- 0.9 kg; P < 0.01), and waist-to-hip ratio (-0.03 +/- 0.01; P < 0.01) increased. Fasting insulin (-1.4 +/- 0.8 mU/L; P = 0.08) and HOMA of insulin resistance (HOMA-IR) (2.2 +/- 0.3 vs. 1.8 +/- 0.2; P = 0.06) tended to decrease, whereas fasting glucose (-1.6 +/- 1.6 mg/dL), glucose-dependent insulinotropic polypeptide (GIP) (-1.8 +/- 1.0 pmol/L), and glucagon-like peptide 1 (GLP-1) (-0.2 +/- 1.1 pmol/L) were statistically unchanged. Post-OGTT areas under the curve (AUCs) for GIP (2,068 +/- 1,134 vs. 2,645 +/- 1,248 [pmol/L] x min; P < 0.01) and GLP-1 (2,352 +/- 796 vs. 2,712 +/- 1,015 [pmol/L] x min; P < 0.01) increased. In TW, body weight tended to increase (1.4 +/- 0.8 kg; P = 0.07) with decreasing FFM (-2.3 +/- 0.4 kg; P < 0.01) and waist-to-hip ratio (-0.03 +/- 0.01; P < 0.01). Insulin (3.4 +/- 0.8 mU/L; P < 0.01) and HOMA-IR (1.7 +/- 0.1 vs. 2.4 +/- 0.2; P < 0.01) rose, fasting GIP (-1.4 +/- 0.8 pmol/L; P < 0.01) and AUC GIP dropped (2,524 +/- 178 vs. 1,911 +/- 162 [pmol/L] x min; P < 0.01), but fasting glucose (-0.3 +/- 1.4 mg/dL), GLP-1 (1.3 +/- 0.8 pmol/L), and AUC GLP-1 (2,956 +/- 180 vs. 2,864 +/- 93 [pmol/L] x min) remained unchanged. CONCLUSIONS In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization.
U2 - 10.2337/dc19-1061
DO - 10.2337/dc19-1061
M3 - Journal article
C2 - 31740479
VL - 43
SP - 411
EP - 417
JO - Diabetes Care
JF - Diabetes Care
SN - 0149-5992
IS - 2
ER -
ID: 235920792